Gut Microbiome May Alter ALS Progression in Mice

In 1993, amyotrophic lateral sclerosis (ALS) was linked to a genetic mutation in the SOD1 gene. It was a landmark discovery, as were others like it at the time linking neurological diseases to heritable, genetic sources. For example, APO-E, the gene linked to Alzheimer’s disease, was discovered in the same year and the gene for Parkinson’s disease just a few years later.

Spotlight

Design Therapeutics

We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™

OTHER ARTICLES
MedTech

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 20, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
MedTech

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 12, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More
MedTech

Next-Gen Gene Therapy to Counter Complex Diseases

Article | July 11, 2022

Gene therapy has historically been used to treat disorders with in-depth knowledge caused by a single genetic mutation. Thanks to the introduction of new generation technologies, the potential of gene therapy is expanding tAo treat diseases that were previously untreatable. Evolution of Gene Therapy One of the major success stories of the twenty-first century has been gene therapy. However, it has not been the same in the past. The field's journey to this point has been long and mostly difficult, with both tragedy and triumph along the way. Initially, genetic disorders were thought to be untreatable and permanently carved into the genomes of individuals unfortunate enough to be born with them. But due to the constant technological advancement and research activities, gene therapy now has the potential to treat various genetic mutation-causing diseases with its ability to insert a new copy and replace faulty genes. Gene Therapy is Finding New Roads in the Medical Sector Gene therapy can help researchers treat a variety of conditions that fall under the general heading of epilepsy, instead of only focusing on a particular kind of disorder brought on by a genetic mutation. Following are some of the domains transformed by gene therapy. Neurology – Gene therapy can be used for the treatment of seizures by directly injecting it into the area causing an uncontrolled electrical disturbance in the brain. Furthermore, by using DNA sequences known as promoters, gene therapy can be restricted to specific neurons within that area. Ophthalmology – Genetic conditions such as blindness can be caused due to the mutation of any gene out of over 200 and resulting in progressive vision loss in children. With advanced gene therapies such as optogenetics, lost photoreceptor function can be transferred to the retinal cells, which are responsible for relaying visual information to the brain. This might give patients the ability to navigate in an unknown environment with a certain level of autonomy. The Future of Gene Therapy The news surrounding gene therapy has been largely favorable over the past few years, with treatment after treatment obtaining regulatory approvals, successful clinical trials, and garnering significant funds to begin development. With more than 1,000 clinical trials presently underway, the long-awaited gene therapy revolution might finally be here.

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Spotlight

Design Therapeutics

We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™

Related News

AI

eureKARE and DNAlytics Form Partnership to Develop a Proprietary AI Platform

eureKARE | July 07, 2021

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with new science and then attempt to find an issue to address with it, eureKARE's methodology reverses this. eureKARE is committed to first finding an unmet need and then enlisting the best scientists and experts to provide an innovative solution to launch exciting new ventures. This process will be aided by eureKARE's one-of-a-kind AI platform, which will assist the business in identifying top academic researchers, locating new ideas and approaches in development, and scaling existing portfolio companies. About eureKARE eureKARE is a ground-breaking new company focusing on financing and establishing next-generation biotechnology start-ups in the microbiome and synthetic biology cutting-edge areas. eureKARE employs a two-step investing strategy to create long-term value. Through its biotech start-upstart-up studios eureKABIOME (Microbiome) and eureKASYNBIO, the company promotes translational research by developing and financing new companies based on high-value European science (Synthetic biology). In addition, the company aims to engage in more mature biotech companies. It will systematically propose to provide some liquidity to early investors, thus fulfilling a crucial demand in the European biotech sector. EureKARE has a fast-expanding portfolio of companies with the potential to disrupt the life sciences sector, led by its prominent founder, Alexandre Mouradian, and a pan-European team. About DNAlytics DNAlytics is based in Louvain-la-Neuve, Belgium, specializing in data science for the healthcare sector, including data management, bioinformatics, biostatistics, Machine Learning, and other Artificial Intelligence methods. DNAlytics products are utilized in clinical research, the creation of biotech drugs and medical devices, public health studies, and the monitoring and optimization of bio-manufacturing processes. In addition, DNAlytics assists a wide range of clients and partners in extracting scientifically sound observations and practical conclusions from complex data sets.

Read More

Gut Microbiome Donations from the Old Invigorate the Young

GEN | November 15, 2019

Youth may be wasted on the young, but not elderliness—not when the elderliness manifests in the gut as a mature microbiome. In experiments led by scientists in Singapore, gut microbes from old mice (24 months old) were transplanted into young, germ-free mice (6 weeks old). After eight weeks, the young mice had increased intestinal growth and production of neurons in the brain, known as neurogenesis. The research team, which was based at Nanyang Technological University (NTU), showed that the increased neurogenesis was due to an enrichment of gut microbes that produce a specific short chain fatty acid, called butyrate. The scientists suggest that butyrate helps the old mice counter some of aging’s debilitating effects. In addition, the scientists speculate that butyrate-enriched foods could help slow aging, benefiting the young—and possibly the old and butyrate-deprived, too.

Read More

Microbiome Influenced by Genetic Differences in Immune System

GEN | October 16, 2019

Scientists headed by a team at the University of Chicago have shown how genetic differences in the immune system can impact on the types of bacterial communities that colonize the gastrointestinal system. Their studies, in germ-free mice colonized with microbiomes from conventionally reared animals, found that while the makeup of the donor microbiome was the key factor in determining the recipient microbiome, genetic differences in the immune systems of the recipients also played a role. “When the input is standardized, you can compare mice of different genetic strains and see what these genetics do to the microbiome in recipient mice,” said Alexander Chervonsky, MD, PhD, who is a senior author of the team’s study, which is published in Cell Reports. “This approach allowed us to tell whether there was a genetic influence, and indeed there is.” Chervonsky and colleagues report their findings in a paper titled, “Polymorphic Immune Mechanisms Regulate Commensal Repertoire.” The bacteria that naturally live in and on us provide essential functions that are required for our very survival, the authors wrote. The composition of microbial communities varies between individuals and is influenced by a range of factors, including “… the mode of transmission during birth, breastfeeding, alimentary infections, and diet.” Previous studies have suggested that host genetics can also impact on microbial communities—identical twins tend to have more similar microbiomes than do non-identical twins—but, as the team continued, “ … two important questions remain unanswered: to what extent and which host’s polymorphic mechanisms are involved in shaping the repertoire of the commensals.”

Read More

AI

eureKARE and DNAlytics Form Partnership to Develop a Proprietary AI Platform

eureKARE | July 07, 2021

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with new science and then attempt to find an issue to address with it, eureKARE's methodology reverses this. eureKARE is committed to first finding an unmet need and then enlisting the best scientists and experts to provide an innovative solution to launch exciting new ventures. This process will be aided by eureKARE's one-of-a-kind AI platform, which will assist the business in identifying top academic researchers, locating new ideas and approaches in development, and scaling existing portfolio companies. About eureKARE eureKARE is a ground-breaking new company focusing on financing and establishing next-generation biotechnology start-ups in the microbiome and synthetic biology cutting-edge areas. eureKARE employs a two-step investing strategy to create long-term value. Through its biotech start-upstart-up studios eureKABIOME (Microbiome) and eureKASYNBIO, the company promotes translational research by developing and financing new companies based on high-value European science (Synthetic biology). In addition, the company aims to engage in more mature biotech companies. It will systematically propose to provide some liquidity to early investors, thus fulfilling a crucial demand in the European biotech sector. EureKARE has a fast-expanding portfolio of companies with the potential to disrupt the life sciences sector, led by its prominent founder, Alexandre Mouradian, and a pan-European team. About DNAlytics DNAlytics is based in Louvain-la-Neuve, Belgium, specializing in data science for the healthcare sector, including data management, bioinformatics, biostatistics, Machine Learning, and other Artificial Intelligence methods. DNAlytics products are utilized in clinical research, the creation of biotech drugs and medical devices, public health studies, and the monitoring and optimization of bio-manufacturing processes. In addition, DNAlytics assists a wide range of clients and partners in extracting scientifically sound observations and practical conclusions from complex data sets.

Read More

Gut Microbiome Donations from the Old Invigorate the Young

GEN | November 15, 2019

Youth may be wasted on the young, but not elderliness—not when the elderliness manifests in the gut as a mature microbiome. In experiments led by scientists in Singapore, gut microbes from old mice (24 months old) were transplanted into young, germ-free mice (6 weeks old). After eight weeks, the young mice had increased intestinal growth and production of neurons in the brain, known as neurogenesis. The research team, which was based at Nanyang Technological University (NTU), showed that the increased neurogenesis was due to an enrichment of gut microbes that produce a specific short chain fatty acid, called butyrate. The scientists suggest that butyrate helps the old mice counter some of aging’s debilitating effects. In addition, the scientists speculate that butyrate-enriched foods could help slow aging, benefiting the young—and possibly the old and butyrate-deprived, too.

Read More

Microbiome Influenced by Genetic Differences in Immune System

GEN | October 16, 2019

Scientists headed by a team at the University of Chicago have shown how genetic differences in the immune system can impact on the types of bacterial communities that colonize the gastrointestinal system. Their studies, in germ-free mice colonized with microbiomes from conventionally reared animals, found that while the makeup of the donor microbiome was the key factor in determining the recipient microbiome, genetic differences in the immune systems of the recipients also played a role. “When the input is standardized, you can compare mice of different genetic strains and see what these genetics do to the microbiome in recipient mice,” said Alexander Chervonsky, MD, PhD, who is a senior author of the team’s study, which is published in Cell Reports. “This approach allowed us to tell whether there was a genetic influence, and indeed there is.” Chervonsky and colleagues report their findings in a paper titled, “Polymorphic Immune Mechanisms Regulate Commensal Repertoire.” The bacteria that naturally live in and on us provide essential functions that are required for our very survival, the authors wrote. The composition of microbial communities varies between individuals and is influenced by a range of factors, including “… the mode of transmission during birth, breastfeeding, alimentary infections, and diet.” Previous studies have suggested that host genetics can also impact on microbial communities—identical twins tend to have more similar microbiomes than do non-identical twins—but, as the team continued, “ … two important questions remain unanswered: to what extent and which host’s polymorphic mechanisms are involved in shaping the repertoire of the commensals.”

Read More

Events